The FDA has noted both the lack of human clinical trial data and uncertainty about long-term safety
These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
Structure Sequence: Tyr-Leu-Glu-Glu-Ala-Tyr-Ser-Ile-Leu-Ser-Arg-Lys-Leu-Gln-Thr-Ser Molecular Formula: CHNOS Molecular Weight: ~1,811 Da PubChem CID: Not applicable (synthetic peptide)
View details GLP-1 & Metabolic Tirzepatide Tirzepatide is a synthetic peptide that functions as a dual pathway agonist, designed as a once-weekly investigational compound studied in preclinical laboratory models for receptor-mediated signaling and modulation of downstream cascades
once opened, follow supplier beyond-use guidance
Drager and Mullen have developed a short peptide (H1-S6A.F8A) from the HI3 region that interacts with c-Myc and prevents it from binding to DNA